Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma

Jorge Marrero, Mary A. Maluccio, Heather McCurdy, Ghassan K. Abou-Alfa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dr Marrero is a consultant with and serves on the advisory boards for Onyx Pharmaceuticals and Bayer. Dr Maluccio has no relevant financial relationships with commercial interests to disclose. Ms McCurdy is on the speakers' bureau for Onyx Pharmaceuticals. Dr Abou-Alfa and/or his spouse serve as a consultant for Aduro Biotech, Astellas Pharma US, AstraZeneca, Bayer, Celgene, Celsion, Eli Lilly and Company, Exelixis, Genentech, IntegraGen, Jennerex Biotherapeutics, MedImmune, Novartis, Pharmacyclics, Roche, sanofi-aventis, Silenseed, and Vicus Therapeutics. He and/or his spouse have received research grants from Abbott Laboratories, Amgen, Bayer, Eli Lilly and Company, Exelixis, Genentech, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, sanofi-aventis, and Vicus Therapeutics.

Original languageEnglish (US)
Pages (from-to)5-16
Number of pages12
JournalCancer Control
Volume21
Issue number2 SUPPL
StatePublished - Apr 2014

Fingerprint

Hepatocellular Carcinoma
Pharmaceutical Preparations
Consultants
Spouses
Therapeutics
Organized Financing
Research

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Marrero, J., Maluccio, M. A., McCurdy, H., & Abou-Alfa, G. K. (2014). Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. Cancer Control, 21(2 SUPPL), 5-16.

Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. / Marrero, Jorge; Maluccio, Mary A.; McCurdy, Heather; Abou-Alfa, Ghassan K.

In: Cancer Control, Vol. 21, No. 2 SUPPL, 04.2014, p. 5-16.

Research output: Contribution to journalArticle

Marrero, J, Maluccio, MA, McCurdy, H & Abou-Alfa, GK 2014, 'Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma', Cancer Control, vol. 21, no. 2 SUPPL, pp. 5-16.
Marrero J, Maluccio MA, McCurdy H, Abou-Alfa GK. Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. Cancer Control. 2014 Apr;21(2 SUPPL):5-16.
Marrero, Jorge ; Maluccio, Mary A. ; McCurdy, Heather ; Abou-Alfa, Ghassan K. / Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. In: Cancer Control. 2014 ; Vol. 21, No. 2 SUPPL. pp. 5-16.
@article{5d7ee67f92a548ea910d91224fac4c7b,
title = "Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma",
abstract = "Dr Marrero is a consultant with and serves on the advisory boards for Onyx Pharmaceuticals and Bayer. Dr Maluccio has no relevant financial relationships with commercial interests to disclose. Ms McCurdy is on the speakers' bureau for Onyx Pharmaceuticals. Dr Abou-Alfa and/or his spouse serve as a consultant for Aduro Biotech, Astellas Pharma US, AstraZeneca, Bayer, Celgene, Celsion, Eli Lilly and Company, Exelixis, Genentech, IntegraGen, Jennerex Biotherapeutics, MedImmune, Novartis, Pharmacyclics, Roche, sanofi-aventis, Silenseed, and Vicus Therapeutics. He and/or his spouse have received research grants from Abbott Laboratories, Amgen, Bayer, Eli Lilly and Company, Exelixis, Genentech, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, sanofi-aventis, and Vicus Therapeutics.",
author = "Jorge Marrero and Maluccio, {Mary A.} and Heather McCurdy and Abou-Alfa, {Ghassan K.}",
year = "2014",
month = "4",
language = "English (US)",
volume = "21",
pages = "5--16",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "2 SUPPL",

}

TY - JOUR

T1 - Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma

AU - Marrero, Jorge

AU - Maluccio, Mary A.

AU - McCurdy, Heather

AU - Abou-Alfa, Ghassan K.

PY - 2014/4

Y1 - 2014/4

N2 - Dr Marrero is a consultant with and serves on the advisory boards for Onyx Pharmaceuticals and Bayer. Dr Maluccio has no relevant financial relationships with commercial interests to disclose. Ms McCurdy is on the speakers' bureau for Onyx Pharmaceuticals. Dr Abou-Alfa and/or his spouse serve as a consultant for Aduro Biotech, Astellas Pharma US, AstraZeneca, Bayer, Celgene, Celsion, Eli Lilly and Company, Exelixis, Genentech, IntegraGen, Jennerex Biotherapeutics, MedImmune, Novartis, Pharmacyclics, Roche, sanofi-aventis, Silenseed, and Vicus Therapeutics. He and/or his spouse have received research grants from Abbott Laboratories, Amgen, Bayer, Eli Lilly and Company, Exelixis, Genentech, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, sanofi-aventis, and Vicus Therapeutics.

AB - Dr Marrero is a consultant with and serves on the advisory boards for Onyx Pharmaceuticals and Bayer. Dr Maluccio has no relevant financial relationships with commercial interests to disclose. Ms McCurdy is on the speakers' bureau for Onyx Pharmaceuticals. Dr Abou-Alfa and/or his spouse serve as a consultant for Aduro Biotech, Astellas Pharma US, AstraZeneca, Bayer, Celgene, Celsion, Eli Lilly and Company, Exelixis, Genentech, IntegraGen, Jennerex Biotherapeutics, MedImmune, Novartis, Pharmacyclics, Roche, sanofi-aventis, Silenseed, and Vicus Therapeutics. He and/or his spouse have received research grants from Abbott Laboratories, Amgen, Bayer, Eli Lilly and Company, Exelixis, Genentech, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, sanofi-aventis, and Vicus Therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84904423595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904423595&partnerID=8YFLogxK

M3 - Article

C2 - 24681845

AN - SCOPUS:84904423595

VL - 21

SP - 5

EP - 16

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 2 SUPPL

ER -